Terms: = Prostate cancer AND ALDH2, ALDHI, 217, ENSG00000111275, ALDH-E2, P05091, MGC1806, ALDM AND Prognosis
19 results:
1. FTO-stabilized miR-139-5p targets ZNF217 to suppress prostate cancer cell malignancies by inactivating the PI3K/Akt/mTOR signal pathway.
Azhati B; Reheman A; Dilixiati D; Rexiati M
Arch Biochem Biophys; 2023 Jun; 741():109604. PubMed ID: 37080415
[TBL] [Abstract] [Full Text] [Related]
2. The prognostic nomogram for PSA-incongruent low-risk prostate cancer treated by radical prostatectomy.
Wang Y; Zhu Y; Fan L; Liu J; Pan J; Xue W
Int Urol Nephrol; 2023 Jun; 55(6):1447-1452. PubMed ID: 37017821
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced prostate cancer: Differences in Genomic Landscape Based on Race.
Zimmerman R; Bilen MA; Heath EI; Nandagopal L; Swami U; Kessel A; Jaeger E; Wesolowski S; Hernanadez EJ; Chipman J; Mack A; Ravindranathan D; Maughan BL; Nussenzveig R; Yandell M; Kohli M; Lilly MB; Sartor AO; Agarwal N; Barata PC
Oncologist; 2022 Oct; 27(10):e815-e818. PubMed ID: 36036607
[TBL] [Abstract] [Full Text] [Related]
4. Development and validation of a cell cycle progression signature for decentralized testing of men with prostate cancer.
Kuhl V; Clegg W; Meek S; Lenz L; Flake DD; Ronan T; Kornilov M; Horsch D; Scheer M; Farber D; Zalaznick H; Cussenot O; Compérat E; Cancel-Tassin G; Wild PJ; Chun FK; Mandel P; Moinfar F; Cohen T; Delee S; Kronenwett R; Doedt J
Biomark Med; 2022 Apr; 16(6):449-459. PubMed ID: 35321552
[TBL] [Abstract] [Full Text] [Related]
5. Development and Validation of a Prognostic Survival Model With Patient-Reported Outcomes for Patients With cancer.
Seow H; Tanuseputro P; Barbera L; Earle C; Guthrie D; Isenberg S; Juergens R; Myers J; Brouwers M; Sutradhar R
JAMA Netw Open; 2020 Apr; 3(4):e201768. PubMed ID: 32236529
[TBL] [Abstract] [Full Text] [Related]
6. Impact of mixed cryoglobulinemia on patients with spontaneous hepatitis C virus clearance: A 13-year prospective cohort study.
Lee KC; Cheng YT; Lin CY; Kuo CJ; Chien RN; Yeh CT; Chang ML
Eur J Clin Invest; 2020 Jan; 50(1):e13189. PubMed ID: 31782138
[TBL] [Abstract] [Full Text] [Related]
7. Evaluation of prostate cancer Stage Groups Updated in the 8th Edition of the American Joint Committee on cancer Tumor-Node-Metastasis Staging Manual.
Lee H; Lee M; Byun SS; Lee SE; Hong SK
Clin Genitourin Cancer; 2019 Feb; 17(1):e221-e226. PubMed ID: 30472041
[TBL] [Abstract] [Full Text] [Related]
8. Abiraterone acetate treatment in patients with castration-resistant prostate cancer with visceral metastases: a real-world experience.
Facchini G; Cavaliere C; D'Aniello C; Iovane G; Rossetti S
Anticancer Drugs; 2019 Feb; 30(2):179-185. PubMed ID: 30320608
[TBL] [Abstract] [Full Text] [Related]
9. Genes involved in prostate cancer progression determine MRI visibility.
Li P; You S; Nguyen C; Wang Y; Kim J; Sirohi D; Ziembiec A; Luthringer D; Lin SC; Daskivich T; Wu J; Freeman MR; Saouaf R; Li D; Kim HL
Theranostics; 2018; 8(7):1752-1765. PubMed ID: 29556354
[TBL] [Abstract] [Full Text] [Related]
10. Secondary tumors of the GI tract: origin, histology, and endoscopic findings.
Gilg MM; Gröchenig HP; Schlemmer A; Eherer A; Högenauer C; Langner C
Gastrointest Endosc; 2018 Jul; 88(1):151-158.e1. PubMed ID: 29476848
[TBL] [Abstract] [Full Text] [Related]
11. Survival analysis of malignant epidural spinal cord compression after palliative radiotherapy using Tokuhashi scoring system and the impact of systemic therapy.
Mui WH; Lam TC; Wong FCS; Sze WK
Ann Palliat Med; 2017 Dec; 6(Suppl 2):S132-S139. PubMed ID: 29156895
[TBL] [Abstract] [Full Text] [Related]
12. [Clinical Characteristics of prostate Ductal Adenocarcinoma in Kyoto University Hospital].
Nakamura K; Terada N; Kobayashi T; Sugino Y; Yamasaki T; Matsui Y; Imamura M; Okubo K; Kamba T; Yoshimura K; Ogawa O
Hinyokika Kiyo; 2015 Dec; 61(12):487-91. PubMed ID: 26790762
[TBL] [Abstract] [Full Text] [Related]
13. 18F-fluoride PET used for treatment monitoring of systemic cancer therapy: results from the National Oncologic PET Registry.
Hillner BE; Siegel BA; Hanna L; Duan F; Quinn B; Shields AF
J Nucl Med; 2015 Feb; 56(2):222-8. PubMed ID: 25593113
[TBL] [Abstract] [Full Text] [Related]
14. High expression of QSOX1 reduces tumorogenesis, and is associated with a better outcome for breast cancer patients.
Pernodet N; Hermetet F; Adami P; Vejux A; Descotes F; Borg C; Adams M; Pallandre JR; Viennet G; Esnard F; Jouvenot M; Despouy G
Breast Cancer Res; 2012 Oct; 14(5):R136. PubMed ID: 23098186
[TBL] [Abstract] [Full Text] [Related]
15. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients.
Lotan TL; Gurel B; Sutcliffe S; Esopi D; Liu W; Xu J; Hicks JL; Park BH; Humphreys E; Partin AW; Han M; Netto GJ; Isaacs WB; De Marzo AM
Clin Cancer Res; 2011 Oct; 17(20):6563-73. PubMed ID: 21878536
[TBL] [Abstract] [Full Text] [Related]
16. Prediction of prognosis after radical cystectomy for pathologic node-negative bladder cancer.
Park E; Ha HK; Chung MK
Int Urol Nephrol; 2011 Dec; 43(4):1059-65. PubMed ID: 21626133
[TBL] [Abstract] [Full Text] [Related]
17. Conditional median survival of patients with advanced carcinoma: surveillance, epidemiology, and end results data.
Kato I; Severson RK; Schwartz AG
Cancer; 2001 Oct; 92(8):2211-9. PubMed ID: 11596040
[TBL] [Abstract] [Full Text] [Related]
18. Do men with prostate or colorectal cancer seek different information and support from women with cancer?
Boudioni M; McPherson K; Moynihan C; Melia J; Boulton M; Leydon G; Mossman J
Br J Cancer; 2001 Sep; 85(5):641-8. PubMed ID: 11531244
[TBL] [Abstract] [Full Text] [Related]
19. Prognostic implications of a positive apical margin in radical prostatectomy specimens.
Fesseha T; Sakr W; Grignon D; Banerjee M; Wood DP; Pontes JE
J Urol; 1997 Dec; 158(6):2176-9. PubMed ID: 9366338
[TBL] [Abstract] [Full Text] [Related]
